Department of Chemistry

 

Document Type

Article

Date of this Version

11-13-2024

Citation

Trujillo-Gonzalez I, Thomes PG, Sakallioglu IT and Kharbanda KK (2024) Editorial: Leveraging multi-omics approaches to understand and manage gastrointestinal and hepatic diseases. Front. Pharmacol. 15:1529088. doi: 10.3389/fphar.2024.1529088

Comments

Open access.

Abstract

The Research Topic “Leveraging multi-omics approaches to understand and manage gastrointestinal and hepatic diseases” proposed by the Frontiers in Pharmacology has attracted a total of four articles on preclinical studies that were covered in three original research manuscripts and one review article. Two research articles were on metabolic dysfunction-associated steatotic liver disease (MASLD), previously named non-alcoholic fatty liver disease (NAFLD), which is now recognized as a predominant cause of chronic liver disease worldwide, affecting over 30% of the adult population (Teng et al., 2023; Miao et al., 2024). Current pharmacological treatments for MASLD are limited and, until a recent FDA-approved treatment, primarily addressed underlying conditions such as obesity, resulting in a non-standardized therapeutic approach predominantly focused on weight management. This scenario highlights the need for high-throughput, comprehensive alternative strategies to effectively treat MASLD, encompassing basic mechanistic research, pathway analysis, and the identification of novel drug targets. Additionally, advanced technologies, including untargeted omics methods and approaches that consider inter-organ communication, are essential for advancing therapeutic strategies for this complex disease.

Share

COinS